EFFORTLESS Trial Of Boston Scientific’s S-ICD Headlines HRS 2016
This article was originally published in Clinica
Executive Summary
Results from 985 patients in EFFORTLESS, the largest post-market registry of Boston Scientific’s S-ICD (subcutaneous ICD), support the technology as an option for a broad population of ICD candidates, according to Lucas V. A. Boersma, an electrophysiologist at St. Antonius Hospital in The Netherlands. He presented data from the registry on May 6 at the Heart Rhythm Society Scientific Sessions in San Francisco.
You may also be interested in...
St. Jude Pauses LEADLESS II Trial Of Nanostim Following Reports Of Lost Telemetry
No patient injuries related to the Nanostim issues have been reported, but it puts St. Jude further behind Medtronic and Boston Scientific in the emerging leadless pacemaker market. The company says the problem reported with seven Nanostim devices is not related to the lithium-deposit problem that recently caused batter depletion in some of its high voltage devices.
News We’re Watching: FDA Approves Medtronic's Affera, Roche's CGM Moves Closer To Approval, And More
Medtech Insight's News We're Watching covers medtech industry and research news you may have missed. This week, the Advanced Technologies and Treatments for Diabetes (ATTD) conference in Florence, Italy, included new results from studies of Roche's continuous glucose monitor and Medtronic's 780G insulin pump, Medtronic moved closer to earning FDA approval for its Affera ablation mapping and ablation system, and Linus Health expanded its technology for finding signs of cognitive problems in speech data.
New’s We’re Watching: J&J's Varipulse PFA Earns CE Mark; Labs Create Intravascular Robots; And More
Medtech Insight's News We're Watching highlights some recent business and R&D developments you may have missed. This week, Biosense Webster’s Varipulse PFA platform earned a CE mark; Biosense Webster also announced the start the pivotal IDE study of its Laminar left atrial appendage elimination system; the FDA approved Boston Scientific's Agent paclitaxel-coated balloon and cleared Medtronic's OsteoCool 2.0 bone ablation system; three papers in Science Robotics describe magnetically controlled vascular robots that could go places wires and catheters cannot.